Company news
Echoiq Limited (ASX:EIQ) news
Echoiq Limited news releases on 6ix. Latest, Sep 16, 2026: EchoSolv HF FDA application update
Press releases & updates
EchoSolv HF FDA application update
September 16, 2026
EchoSolv HF FDA Application Update
September 8, 2026
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
Quarterly Activities Report & Appendix 4C Cashflow Report
July 26, 2026
Exclusive Imaging Dataset Strengthens AI Competitive Moat
July 1, 2026
Echo IQ Raises A$110m via Institutional Placement
June 30, 2026
EchoIQ Strengthens Leadership Team and Clinical Advisory Network to Accelerate Next Phase of Commercial Growth and U.S. FDA Initiatives
June 24, 2026
Research collaboration secured with Mayo Clinic
June 11, 2026
$762k R&D Tax Incentive Received
May 25, 2026
Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
April 30, 2026
QuarterlyActivities Report and Appendix 4C Cash Flow Report
April 29, 2026
EchoSolv AS deployed into Mount Sinai Health System
April 27, 2026
Agreement with Mayo Clinic for EchoSolv HF
March 23, 2026
Update - S&P DJI March 2026 Rebalance of the All Ordinaries
March 10, 2026
S&P DJI Announces March 2026 Quarterly Rebalance
March 6, 2026
Appendix 4D 31 December 2025
February 26, 2026
Quarterly Activities Report and Appendix 4C Cash Flow Report
January 23, 2026
Response to ASX Price Query
January 22, 2026
Formal lodgement of FDA submission for EchoSolv HF
December 14, 2025
Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December
December 8, 2025
Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results
November 24, 2025
Exceptional Results from Validation Study for EchoSolv HF
November 23, 2025
Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 21, 2025
Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025
November 12, 2025
Quarterly Activities and Appendix 4C Cash Flow Report
October 30, 2025
Category III CPT code application update
October 6, 2025
Trading Halt
October 5, 2025
Pause in Trading
October 5, 2025
Strong Operational Momentum
October 2, 2025
Update on Category III CPT Code Application
September 19, 2025
Preliminary Final Report
August 29, 2025
Quarterly Activities & Appendix 4C Cashflow Reports
July 24, 2025
Reseller Agreement Secured with SARC MedIQ
July 10, 2025
Mayo Clinic Validation Study Underway
July 1, 2025
Echo IQ raises $17.3m via institutional placement
May 7, 2025
Listing on the OTCQB Market
April 16, 2025
Echosolv Collaboration Agreement with Mayo Clinic Platform
April 2, 2025
ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS
April 1, 2025
Expansion Across 36 US Hospitals and Cardiology Practices
March 30, 2025
Investor Webinar Presentation
March 6, 2025
Strong Progress in First Two Months of CY25 Achieved
March 4, 2025
Appendix 4D 31 December 2024
February 27, 2025
$1.26M R&D TAX INCENTIVE RECEIVED
February 12, 2025
Response to ASX Query Letter
January 31, 2025
PRE-SUBMISSION MEETING WITH US FDA FOR HEART FAILURE
December 23, 2024
The First Step in EIQs US Market Commercialisation Strategy
December 8, 2024
S&P DJI Announces December 2024 Quarterly Rebalance
December 6, 2024
EIQ signs integration agreement with Flagship US Hospital
November 17, 2024
US Based CEO Appointed to Execute Commercialisation Strategy
October 8, 2024
Major Milestone Achieved with FDA Clearance for EchoSolv AS
October 7, 2024